Trials / Terminated
TerminatedNCT03175172
Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM)
A Phase 2 Single-arm Study to Evaluate Safety and Efficacy of CRS-207 With Pembrolizumab in Adults With Previously-Treated Malignant Pleural Mesothelioma
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Aduro Biotech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate whether CRS-207 with pembrolizumab is safe and effective in adults with MPM who have failed prior anti-cancer therapy.
Detailed description
The population for this study will consist of approximately 35 adults with histologically-confirmed MPM (epithelial or biphasic) whose disease has progressed after 1-2 prior anti-cancer therapies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CRS-207 | Administered by IV infusion over approximately 1 hour. |
| BIOLOGICAL | Pembrolizumab | Administered by IV infusion over approximately 30 minutes. |
Timeline
- Start date
- 2017-05-31
- Primary completion
- 2018-01-09
- Completion
- 2018-01-31
- First posted
- 2017-06-05
- Last updated
- 2019-04-04
- Results posted
- 2019-02-19
Locations
8 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03175172. Inclusion in this directory is not an endorsement.